Archive | May, 2012

Risk Still OFF with Euro Malaise

Look for biotechnology intermediate top as we approach ASCO next week. Market is now driven by hedgies and big funds.IBB  ($123.90) double top with YTD high of  $126.90 Mid cap biotech index off 1.7%. DX and tools also very weak. S&P unchanged from one year ago.

Continue Reading 0

Notes from B Riley 13th Annual Investor Conference: CEMI,VRML

There were some excellent small cap companies presenting at the B. Riley Investor Conference in Santa Monica this week. Five tracks covered companies in healthcare, technology and energy, consumer/telecom, software and services and internet and media. Our focus within healthcare is biotechnology, tools and clinical diagnostics. Micro-Cap Plays in Clinical Diagnostics Chembio (CEMI.PK  $0.52)  Market […]

Continue Reading 0

Todays’ Sell-Off Finally Hits Resilient Biotech Stocks

Facebook Hype Effect-Sell MO Stocks? Many of the favorite momentum stocks are being hit with profit taking today including large cap biopharmaceutical stocks. With the NASDAQ down 0.8% at 2850,  we see a lot of countertrends like gold up $39.70 off recent lows to $1576 accompanied by a big rally in silver and other metal stocks […]

Continue Reading 0

Biotech Sector Avoids Nasty Correction and Hits New Highs

Why is the biotechnology sector still strong? Despite all the gloom and doom in the markets over the past 60 days the biotechnology sector has barely flinched and is currently at YTD highs. Bellwether ETFs IBB (126) and XBI ($82.85) are up over 20% YTD after a brief correction in mid-April compared to the S&P […]

Continue Reading 0

Rayno Life Science -Biomarkers: BGMD,VRML

Biomarker MicroCap Face-Off: BGMD vs VRML Vermillion announced Q1 Results today today with OVA1 revenues of $312K of which $114 k was licensing revenues from their testing partner Quest Diagnostics Inc.(DGX $57). Operating expenses were down to $2.4M compared to$4.8M in the same period a year ago for a Q1 Net Loss of  $1.8M or […]

Continue Reading 0

Rayno Life Science: DX and Tools Update ALR 5/11/12

More Bad News on Alere The second shoe has dropped on Alere (ALR $19) with the stock off 15% as the FDA inspection news regarding manufacturing and quality at the “Biosite”facility.Leerink Swann downgraded the stock to “Market Perform” after trying to support the stock earlier but there is downside risk with potential product recalls and […]

Continue Reading 0

Rayno Life Science Update-Macro Rules, Risk Off

Market Off Its Lows Today-Consumer Cyclical and Technology Outperforming Healthcare The market continues to be weak with the NASDAQ entering its 5th day of the sell-off  down 4.29% but the QQQ ($64.29) NASDAQ-100 has recovered from lows today. The ETF IBB ($64.32) has fared better down only 1.92% over five days and still up 18% YTD […]

Continue Reading 0

Market Sell-Off Continues: Biotechs Follow NASDAQ Down 1.56%

The NASDAQ Biotechnology Index IBB ($122.30)  is off 1.5% today and more than 2% off its all time high of $126.65. The first clue to the current sell-off was a CNBC Fast Money Contributor to buy the ETF XBI ($79) earlier in the week at its top of $82. Earlier this week we urged investors […]

Continue Reading 0

Alere Inc.(ALR) : Where is the bottom and what went wrong?

ALR ($21.58) Continues to Sell-off Slicing through 3 Mo. Technical Bottom We have included Alere in our diagnostics and tools portfolio since 2/2/09 at a price of $25, and although the stock is trading more than 10% under that price 3 years later, there was an opportunity to get out in the 40’s with a […]

Continue Reading 0